Using NAUSP/EMM data to monitor surgical antimicrobial prescribing

Determining quality improvement targets for surgical prophylaxis

Kathryn Daveson and Alexandra Marmor @kathryndaveson



Surgical Antimicrobial Prophylaxis Prescribing

Australian Context



SAP: Qualitative Prescribing


NAPS

- inpatient prescribing, procedure last 24 hours assessed
- extended prophylaxis peri-operative not assessed

SNAPS


- Min 30 episodes/one week
- Patient "antibiotic prescription" journey

State and territory specific audits – 5x5, surgical specific audits



Common indications in Hospital NAPS, 2013-2017

Commonly prescribed antimicrobials in Hospital NAPS, 2013-2017



SAP Australia: NAPS

Table 7 Hospital NAPS key indicators, 2013-2017

Key Indicator		Percentage of total prescriptions (%)					
		2014	2015	2016	2017		
Indication documented in medical notes (best practice >95%)	70.9	74.0	72.5	75.6	77.7		
Review or stop date documented (best practice >95%)	na	na	35.5	38.1	40.5		
Surgical prophylaxis given for >24 hours (best practice <5%)*	41.8	35.9	27.4	31.1	30.5		
Compliant with Therapeutic Guidelines or local guidelines†	72.2	/3./	70.6	65.4	67.3		
Appropriate (optimal and adequate)§	75.6	75.9	77.0	76.1	76.5		

SAP Australia: SNAPS

Procedural prescribing

- 1 in 2 intra-operative prescriptions inappropriate
 - Incorrect timing (47%)

Post-procedural prescribing

- 57% cefazolin
- 2/5 post-procedural antibiotics are not required

Number of post-procedural antimicrobial prescriptions by percentage appropriateness for each surgical procedure group, SNAPS contributor hospitals, 2016





Figure 18 Reasons for inappropriateness, percentage and number of post-procedural antimicrobial prescriptions for prophylaxis#




^{# (}n = 346) where post-procedural antimicrobial prophylaxis was required

Surgical Antimicrobial Prophylaxis Prescribing

Canberra Context





CHS focus


Bias: 30 scripts per specialty

- Inpatient timing
- Cefazolin duration
- Topical chloramphenicol

• How to monitor cefazolin improvements??

NAUSP and Definitions

- Measure of quantity of use
- Defined daily doses per OBDs



Non-ICU usage: cefazolin

- Australia (PR) 14% total antimicrobial use (111 DDD/OBD)
- CHS 15.1% (116 DDD/OBD)

Aim


A majority of cefazolin use is for SAP and is captured by the National Antimicrobial Usage Surveillance Program (NAUSP) due to dual prescribing processes (EMM + paper)

We aimed to determine if NAUSP/EMM data could be used to monitor quality improvement reductions in cephazolin prescribing and what targets we would use.

"Real time" feedback (by week/month) – OBD delays

Why not run charts?

- Valuable QI tool
- Likely weekly reporting
- Resourcing variable for run charts
- Delayed reporting if extended prophylaxis (but could use >24 hours)



A typical run chart


• Didn't have mandatory indications

Methods

Audit of ward prescribing electronic medication management (EMM) data (4/52) - (all prescriptions week one then 25 scripts per week) Proportion of hospital cefazolin used for SAP and appropriate Total DDDs - administered (EMM):dispensed (non-ICU NAUSP)

NAUSP quality improvement target modelled based on a 50% improvement in the guideline compliance of cephazolin used for postoperative SAP.

Cephazolin



65% of all scripts were for SAP

Fifty-five percent of cephazolin EMM **prescription indications** were for SAP

No post-operative scripts were compliant with guidelines (TG 2014).

*Soft tissue infection in the presence of a penicillin allergy (n=2)

Results


Table 21 Defined adding a doses a DDDs) ab fate phazolina sed abnahe a wards, aby and ication, 27 CH, 21 ul-Dec 22 018.2

		EMMæstimates®bf®DDDs@administered®			NAUSP ® DDDs®	
Month⊡		Total₪	Surgical prophylaxis*	Other2 Indications*2	dispensed	
2018?	Aug?	1753?	9642	7892	2368🛚	
	Sep?	1441?	793?	649?	21092	
	Oct?	17852	982?	803?	2738?	
	Nov?	16542	910?	744?	2513?	
	Dec?	16612	913?	747?	2071?	
20192	Jan?	15022	826?	6762	2212?	
	Feb?	14692	808?	661?	2281?	
	Mar?	16612	913?	747?	2318?	
	Apr?	15322	843?	6892	2359🛭	
	May?	1802?	991?	811?	2587?	
Ave	erage?	1626 ?	894?	732 ?	2356?	

Fifty-five percent of cephazolin EMM **prescription indications** were for SAP, and none of this was compliant with guidelines.


Strong correlation between monthly DDDs of cephazolin measured by NAUSP and EMM (r=0.68, p=0.03)


^{*}Based nather proportion of Management of Ma



Administration: dispensing

Varies 71-88% Paper charts!





An effective quality improvement intervention to improve guideline compliance by 50% would lead to a 19% reduction in NAUSP DDDs. A safe target would be anything >400 DDD (no adjusted for OBD)

Options for future SAP monitoring

 NAUSP data may be useful for monitoring SAP quality improvement interventions, in conjunction with less frequent SNAPS/5x5 or EMM audits.

 We set a quality improvement target of a 10% (average 235 DDD/month) reduction in total hospital use within 6 months.

Local facility application

Decide on resources available

Small audit of cefazolin use: appropriateness

Proportion of cefazolin SAP use

Target

Run charts/
EMM/
NAUSP usage

Thanks

- Alexandra Marmor
- Dr Hayley Heaton
- CHS SAP Working Group
- Infection Prevention and Control Program
- Antimicrobial Stewardship Program

